America’s AI Action Plan, recently announced by the Trump Administration, aims to achieve U.S. dominance in artificial intelligence but overlooks a key force multiplier: investing in the American people’s human brainpower. From design to deployment, AI systems reflect and rely on the cognitive capacities of the people who build and use them. 

American ingenuity—what Lincoln called ‘the fire of genius’—has long been the engine of our productivity and progress. From the space race to Silicon Valley, it’s not just natural resources or industrial capacity that set the U.S. apart, but the cognitive, creative, and entrepreneurial capacity of our people – our brain capital.

The Administration’s stated aim of “powering a new age of American leadership in science, technology, and global influence” will not be achieved by silicon and data infrastructure alone. It must be accompanied by investments in a different kind of infrastructure – our national brain infrastructure.

Just as AI relies on chips, cloud networks, and compute power, its success ultimately depends on the human intelligence that shapes, governs, and applies it. The World Economic Forum has identified the capabilities most essential in the AI era: analytical thinking, resilience, creativity, empathy, and curiosity. These are not technical upgrades – they are human ones. Failing to build brain infrastructure means our most powerful tools may evolve faster than our capacity to direct them.

Despite enormous advances in neuroscience, the brain remains one of the least understood organs in the human body. We know that brain health and performance is shaped by everything from genetics and inflammation to early life experiences and social connection, but we lack a full understanding of how these factors interact—or how to intervene most effectively across populations. Rising rates of mental and neurological health conditions are eroding America’s cognitive resilience – threatening our nation’s capacity to learn, work, innovate, and lead. Further, we know very little about how AI itself may reshape our ability to do these things.

While the U.S. is slashing strategic investments in science, education and health, other nations are doubling down. China, for example, has dramatically expanded its national brain science agenda—accelerating brain-computer interface trials, funding neuro-AI innovation, and integrating neuroscience into its economic and defense strategies.  If America fails to act, it risks ceding not just scientific leadership, but the very foundation of AI competitiveness.

To compete with China and lead the next era of innovation, the U.S. must go beyond chips and deregulation. As many European nations already are developing, the United States needs a national brain capital strategy – a Human Intelligence “H.I.” Action Plan – that will enable us to fully flourish and lead.

Any strategy to power a new age of American leadership must expand the aperture beyond the technology that aids us – to include us. This involves prioritizing early child development and strong education systems, and embedding neuroscience-informed learning in schools. It also requires us to address the health and social risk factors that hamper cognitive resilience, scale cognitive capacity across the workforce through tools, culture and design, incentivize brain health innovation across sectors, and address rising rates of mental and neurological health conditions that plague Americans at all ages.

There is no doubt that AI holds the promise of augmenting and accelerating human productivity and scientific discoveries. But we must remember this is a collaboration. Investing in AI without equally investing in human capacity, ethics, and well-being risks collapsing the very foundation we aim to build. By nearly every meaningful measure – life expectancy, happiness, living standards, equality, cognitive resilience – Americans are falling behind. Our technological ambition must be matched by a human one.

The bottom line: we cannot build intelligent systems without fueling human intelligence. The countries that win the AI age will be those that invest not only in machines – but in the cognitive, emotional, and creative capacity of their people.

The post The Missing Piece in America’s AI Strategy: Brain Capital appeared first on Medika Life.

Now the challenge was to determine the level of her dementia, how it was affecting her lifestyle, and whether or not there might be some hope in a new medication that had just been released for clinical trials. Part of the protocol required that she read something, and other parts that she perform an action, or recall items shown to her, and she would need her glasses for these tests.

When asked to replace her glasses, she looked at them as strange objects and had no idea what to do with them. Turning the glasses over and examining them, she still didn’t understand what they were meant to do.

Her daughter, who accompanied her for the evaluation, was almost in tears as she told me, “It has become even worse when we sit down for dinner because she doesn’t know what is food and what utensils are. She often tries to eat her fork, and we have to stop her.”

The woman was in her early 70s and previously had a successful clothing design business. But there had been noticeable slips in her behavior and even her ability to keep her company’s accounts correct. A math whiz, she kept blaming it on the sunlight coming in through the windows in her office.

She no longer went to the office after daily arguments, and her suspicion regarding her staff disrupted her business. Previously, she enjoyed good interactions with everyone in the office. Most had worked with her for decades and were shocked at her behavior.

The Thief We Fail to Acknowledge

Dementia prevalence increases in direct correlation with age; it reaches 1% in the 60–64 age group and 24–33 % in the 85+ age group. The term “dementia with late onset” refers to the disorder’s emergence after the age of 65, whereas “early-onset dementia” describes its incidence before that age. The signs may be subtle and even experienced clinicians may miss the probable diagnosis of dementia.

Roughly half of the 600 older persons whose brain scans and health indicators were investigated went on to acquire cognitive impairment. In addition to signs of brain aging, they found that the genotype, specific cognitive test scores, hearing loss, memory problems reported by the individual themselves, and symptoms of depression were associated with future cognitive impairment in older persons who were otherwise neurologically healthy.

According to a recent study, people with dementia start losing weight at least ten years before their symptoms appear, and this process speeds up in the two to four years leading up to the diagnosis. Dementia progression may be accelerated by hormonal and metabolic changes associated with weight reduction.

I can remember a neighbor who lived alone, was in her 80s, and went out several times a week to volunteer with, as she said,” the elderly at the local hospital.” No, she never saw herself as elderly or incapable of caring for all of her needs.

But one day, she mentioned to me that she had an evil twin coming into her home and hiding things on her. “I know she’s hiding things,” she said, “because I find them in places I would never have put them.” It was at this point that she stopped preparing food for herself, and I had to arrange for a local senior-support organization to deliver meals to her. But things got worse and she was becoming more mentally unstable until she was evaluated by a healthcare professional from that local hospital.

Once the evaluation was completed and she went to meet a team that worked on a dementia-related unit at the hospital where she had volunteered, she related the story of the evil twin. The decision was made that she could be admitted, and they would care for her.

Within months of arriving on the unit, she was discovered to have advanced cancer, had three surgeries, and died. We will never know if her dementia was related, somehow, to her cancer or the use of pain medication for it.

What Do We Look for?

Some of the subtle and not so subtle changes that should be noted in potential neurocognitive changes:

1. Losing track of newly acquired knowledge. Another symptom is an increase in the frequency with which you need to use memory aides, as well as a tendency to forget crucial dates or events.
2. Difficulty maintaining track of regular expenses or following a tried-and-true recipe.
3. Navigating to a known place, problems with a shopping list, or recalling the rules of a beloved game.
4. Sometimes they need assistance with the microwave’s settings or record a TV program.
5. Perplexed by events that do not unfold in real-time. They could become disoriented and lose track of their way at times.
6. They might also have trouble maintaining balance or reading, seeing colors, or gauging contrast, which could make them dangerous drivers.
7. Difficulty keeping up with or contributing to a discussion. They might repeat themselves or freeze up in the midst of a sentence, leaving you to figure out what to say next. They might not know how to spell certain words, have problems identifying commonplace objects, or even call something the wrong name (such a “watch” being called a “hand-clock”). One thing to remember is that sometimes there are regional names for certain things such as a door knocker may be called something else.
8. Possibly misplace items and not be able to trace their path back to them. As the illness advances, he or she may begin to falsely accuse others of stealing.
9. Perhaps they are careless with their money or do not keep themselves clean. Lack of care for personal cleanliness can also be caused by depression.
10. Do not participate in extracurricular activities, hobbies, or social gatherings. If they have a favorite team or pastime, they could struggle to keep up. And feelings of bewilderment, suspicion, depression, anxiety, or terror may set in. Whether they are at home, with friends, or somewhere else, they could quickly become agitated.

Although there are numerous changes that we may notice, there are a number of other reasons that some of these changes may be due to something else. We know that medication as well as a loss of active involvement in work or some other activity may be the reason for changes in behavior.

Remember, don’t jump to a conclusion that the person is suffering from a cognitive impairment. Go slow, consider everything, and have an evaluation by a healthcare professional.

The post Spotlighting Emerging Dementia in Its Many Iterations and Stages appeared first on Medika Life.

That Reusable Water Bottle Might Be Killing You (Slowly)

A bit hyperbolic, I grant, but the truth might surprise you.

medium.com

You’re Drinking Plastic: How Tea Bags Are Harming Your Gut

I love tea.

medium.com

It’s a topic that keeps becoming more alarming, and a new study has added to the confusion.

We already know these tiny plastic particles, manufactured or broken down from larger plastics, damage our environment.

Past research has linked microplastics to a higher risk of serious illnesses like heart disease, lung disease, and even cancer.

The average person ingests tens of thousands of these particles yearly through the water, food, and air we drink.

New Research on Microplastics and Dementia

And now, this latest research has me even more concerned.

A team led by Dr. Matthew Campen at the University of New Mexico has discovered something disturbing:

Microplastic levels in the brain are significantly higher than in other organs like the liver and kidneys.

This finding, published this month in Nature Medicine, raises serious questions about what these particles do to our brains.

I will explore what this could mean for our health, particularly concerning conditions like dementia.

Polyethylene — Most Common Brain Microplastic

Researchers analyzed brain tissue samples from the New Mexico Office of the Medical Investigator collected between 2016 and 2024.

The study examined human brain microplastic concentrations.

Could these tiny particles pose a threat to our neurological health?

The investigators developed a technique that allowed them to identify 12 polymer types in the brain.

Polyethylene — a plastic widely used in bags, packaging, water pipes, and insulation — was the most common polymer in the brain.

Upon analysis of the study’s findings, researchers found this:

Microplastic concentrations were much greater in the brain than in other body areas, including the liver, kidneys, placenta, and testes.

High Brain Microplastics Linked to Dementia

The association does not imply a causal relationship, but this finding particularly struck me:

Brain tissue from individuals diagnosed with dementia had up to 10 times more microplastics than those without the disease.

Their study showed brain tissue to have a high concentration of micro- and nanoplastics (MNPs).

Their study revealed a high concentration of micro- and nanoplastics (MNPs) in these areas.

This finding raises crucial questions about the mechanisms by which MNPs reach brain tissue, the processes involved, and how they might contribute to nerve degeneration.

Further research is needed to understand these pathways and their potential impact on neurological health.

Protecting Your Brain From Microplastics

Here are some ways you might protect your body (including your brain) from microplastics:

• Use reusable containers, avoiding plastics where possible
• Minimize single-use plastic use (and certainly do not use it over and over)
• Choose foods (including seafood) that are from sources with fewer microplastics

• Minimize ultra-processed food consumption

Potential risk of microplastics in processed foods: Preliminary risk assessment.

pubmed.ncbi.nlm.nih.gov

• Don’t heat plastic food packaging.
• Avoid bottled water. I prefer filtered tap water.
• Vacuum your home frequently. Invest in a HEPA vacuum device.
• Have a good ventilation system at home (and ideally at work, too)
• Wear natural clothing (such as organic cotton or hemp instead of synthetic fibers)
• Avoid air pollution if possible

Remember: Much global plastic production is used to package food and beverages.

However, this plastic is susceptible to wear and tear during use, which fragments the material into tiny particles known as microplastics.

What are your thoughts? Am I overly concerned about microplastics? It is a de minimus risk?

The post Dementia’s Silent Thief: Could Microplastics Be the Culprit? appeared first on Medika Life.

This peer-reviewed study was directed by lifestyle medicine pioneer Dean Ornish, M.D., founder and president of the nonprofit Preventive Medicine Research Institute and clinical professor of medicine at the University of California, San Francisco, in collaboration with other renowned scientists and neurologists from leading academic medical centers. These include:

• Harvard Medical School / Massachusetts General Hospital (Rudolph E. Tanzi, Ph.D.; Steven E. Arnold, M.D.; Dorene Rentz, Psy.D.)
• Karolinska Institute (Miia Kivipelto, M.D., Ph.D.)
• Preventive Medicine Research Institute (Dean Ornish, M.D.; Catherine Madison, M.D.; Colleen Kemp, R.N.; Anne Ornish, B.A.; Sarah Tranter, R.N.; Nancy DeLamarter, M.S.W.; Noel Wingers, M.S.; Carra Richling, R.D.)
• University of California, San Francisco (Dean Ornish, M.D.; Charles E. McCulloch, Ph.D.; Jue Lin, Ph.D.; Kim Norman, M.D.)
• Renown Health Institute of Neurosciences (Jon Artz, M.D.)
• University of California, San Diego (Douglas Galasko, M.D.; Rob Knight, Ph.D.; Daniel McDonald, Ph.D.; Lucas Patel, B.S.)
• Duke University Medical Center (Rima Kaddurah-Daouk, Ph.D.)
• Buck Institute for Research on Aging (Eric Verdin, M.D.)

“I’m cautiously optimistic and very encouraged by these findings, which may empower many people with new hope and new choices,” said Dr. Ornish. “We do not yet have a cure for Alzheimer’s, but as the scientific community continues to pursue all avenues to identify potential treatments, we are now able to offer an improved quality of life to many people suffering from this terrible disease.”

The research team recruited 51 participants with a diagnosis of mild cognitive impairment or early dementia due to Alzheimer’s disease and randomly assigned them to either an intensive lifestyle intervention group (no drugs added) or a usual-care control (comparison) group. Members of the control group were instructed not to make any lifestyle changes during the 20-week trial.

The intervention group participated in an intensive lifestyle program with four components: (1) a whole-foods, minimally processed plant-based diet low in harmful fats, refined carbohydrates, alcohol and sweeteners — predominantly fruits, vegetables, whole grains and legumes, plus selected supplements — with all meals sent to each patient’s home to maximize adherence; (2) moderate aerobic exercise and strength training for at least 30 minutes per day; (3) stress management, including meditation, stretching, breathing and imagery, for one hour per day; and (4) support groups for patients and their spouses or study partners, for one hour three times per week.

Improvements in patients with early Alzheimer’s disease

To measure pre- and post-trial cognitive function, the researchers utilized four standard tests used in Food and Drug Administration drug trials: the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), Clinical Global Impression of Change (CGIC), Clinical Dementia Rating–Sum of Boxes (CDR-SB) and Clinical Dementia Rating Global (CDR-G).

Results after 20 weeks showed overall statistically significant differences between the intervention group and the randomized control group in cognition and function in three of these measures (CGIC, p = 0.001; CDR-SB, p = 0.032; CDR-G, p = 0.037), and differences of borderline significance in the fourth test (ADAS-Cog, p = 0.053). When a mathematical outlier was excluded, all four measures showed significant differences in cognition and function in the experimental group. Three of these measures showed improvement in cognition and function in the intervention group and one test showed significantly less disease progression. In contrast, the randomized control group worsened in all four of these measures.

Not all patients in the intervention group improved; in the CGIC test, 71% improved or were unchanged. In contrast, none of the patients in the control group improved, eight were unchanged and 17 (68%) worsened.

Many patients who experienced improvement reported regaining lost cognition and function. For example, several patients in the intervention group reported that they had been unable to read a book or watch a movie because they kept forgetting what they had just read or viewed and had to keep starting over, but now they were able to do so and retain most of this information. One individual reported that it used to take him weeks to finish reading a book, but after participating in the study he was able to do so in only three or four days and was able to remember most of what he read.

A former business executive reported regaining the ability to manage his own finances and investments. “It was so much a part of my life — who I am, and who I was — it was hard saying that part of me was just gone,” he said. “I’m back to reconciling our finances monthly; I keep up to date on our investments. A lot of self-worth comes back.”

A woman said that for five years she had been unable to prepare their family business financial reports, but now she is able to do so accurately. “A deep sense of identity is returning. It’s given me a new lease on life, and yet it’s a familiarity and something I’ve always prided myself on. I’m coming back like I was prior to the disease being diagnosed. I feel like I’m me again — an older but better version of me.”

There was a statistically significant dose-response correlation between the degree of lifestyle changes in both groups and the degree of change in most measures of cognition and function testing. In short, the more these patients changed their lifestyle in the prescribed ways, the greater was the beneficial impact on their cognition and function.

This dose-response correlation adds to the biological plausibility of these findings and may help to explain, in part, why some patients in the intervention group improved and others did not (although other mechanisms may also play a role). Other studies have shown that more moderate lifestyle changes such as adopting the Mediterranean diet may slow the rate of progression (worsening) of Alzheimer’s disease but may not go far enough to improve cognition and function.

In addition to improvements in cognition and function, the intervention group also demonstrated significant improvements in several key blood-based biomarkers. One of the most clinically relevant biomarkers is called the Aβ42/40 ratio, which is a measure of amyloid, thought to be an important mechanism in Alzheimer’s disease. This measure improved in the lifestyle intervention group (with the presumption that this improvement reflected amyloid moving out of the brain and into the blood), but it worsened in the randomized control group, and these differences were statistically significant (p = 0.003).

There was also a statistically significant dose-response correlation between the degree of lifestyle change and the degree of improvement in this amyloid ratio (p = 0.035). This direction of change in amyloid was also a major finding with lecanemab, a drug approved for treating Alzheimer’s disease last year.

Also, the gut microbiome in the intervention group showed a significant decrease in organisms that raise the risk of Alzheimer’s disease and an increase in organisms that are protective against Alzheimer’s disease. These biomarker and gut microbiome results also add to the biological plausibility of the overall findings.

According to renowned Alzheimer’s scientist Miia Kivipelto, M.D., Ph.D., “These findings add to the growing body of evidence that moderate multimodal lifestyle changes may help prevent Alzheimer’s disease or slow its progression, and also suggest that more intensive multimodal lifestyle changes may have additional benefits for improving cognition in patients with early Alzheimer’s disease.”

New hope in tackling a devastating and costly disease

Alzheimer’s disease, the fifth-leading cause of death among Americans aged 65 and older, is not only physically and emotionally devastating; it’s also extremely costly. The disease currently affects more than six million people in the U.S., at an annual cost of more than $345 billion. By 2050, the number affected is expected to reach 13 million, with costs projected to skyrocket to $1.1 trillion annually.

“There’s a desperate need for Alzheimer’s treatments,” said study co-author Rudolph E. Tanzi, Ph.D., an acclaimed professor of neurology at Harvard Medical School and director of the McCance Center for Brain Health at Massachusetts General Hospital, one of the study’s clinical sites. “Biopharma companies have invested billions of dollars in the effort to find medications to treat the disease, but only two Alzheimer’s drugs have been approved in the past 20 years — one of which was recently taken off the market, and the other is minimally effective and extremely expensive and often has serious side effects such as brain swelling or bleeding into the brain. In contrast, the intensive lifestyle changes implemented in this study have been shown here to improve cognition and function, at a fraction of the cost — and the only side effects are positive ones.”

“I am delighted and honored to be a part of this groundbreaking study showing for the first time in a controlled clinical trial what the epidemiology has told us all along: Lifestyle factors are critically important in our efforts to address Alzheimer’s. While efforts to develop drugs to treat this disease will continue, this study provides a blueprint for practical, easily implemented steps that can significantly alter the progression to full Alzheimer’s disease,” said study co-author Eric Verdin, M.D., president and CEO of the Buck Institute for Research on Aging.

This study has implications for preventing Alzheimer’s disease as well. New technologies such as artificial intelligence now make it possible to predict an individual’s likelihood of developing this disease years before it becomes clinically apparent, but many people ask, “Why would I want to know if I’m likely to get Alzheimer’s disease if I can’t do anything about it? It will just make me worry.” Although further research is needed, it is reasonable to believe that the same intensive lifestyle changes that often improve cognition and function in those with mild cognitive impairment or early dementia due to Alzheimer’s may help prevent the disease as well.

“This study finally gives us scientific data to support what many of us in this field have believed instinctively for years, that lifestyle interventions may determine the trajectory of people’s Alzheimer’s journeys,” said Maria Shriver, founder of the Women’s Alzheimer’s Movement (WAM) at Cleveland Clinic, which provided early seed funding for this study. “We opened the WAM Prevention and Research Clinic at Lou Ruvo Center for Brain Health in Las Vegas for women 30 to 60 years of age who are at higher risk than average for developing Alzheimer’s. The protocols we use involve adopting many of the lifestyle interventions employed in this study. So, showing success in improving the health trajectories of those already diagnosed with Alzheimer’s clearly offers hope to those who want to delay or prevent developing the disease altogether. This is a study to give us hope.”

A growing body of lifestyle medicine research

Dr. Ornish has directed peer-reviewed research at the nonprofit Preventive Medicine Research Institute for over four decades. He is often referred to as “the father of lifestyle medicine.”

The Institute’s studies, published in leading peer-reviewed medical and scientific journals, focus on the power of lifestyle medicine to help prevent and often reverse the progression of many of the most common and costly chronic diseases. These include coronary heart disease, Type 2 diabetes, early-stage prostate cancer, hypertension, hypercholesterolemia, and now, early-stage Alzheimer’s disease.

Dr. Ornish’s most recent bestselling book, “Undo It!,” co-authored with Anne Ornish, puts forth his unifying theory: the reason that the same lifestyle changes may beneficially affect so many different chronic diseases is that these share common biological mechanisms that are directly affected by what people eat, how much they exercise, how they respond to stress, and how much love and support they enjoy. Alzheimer’s is the latest example of why “what’s good for your heart is also good for your brain.”

In 2010, the Centers for Medicare & Medicaid Services (CMS) began providing nationwide Medicare coverage for Dr. Ornish’s program, which has been shown to often reverse the progression of coronary heart disease, as “intensive cardiac rehabilitation.” This nine-week program is offered online, so individuals can join classes from the comfort of their own homes, enabling participation by those who cannot afford to take time off work, who live far from a hospital or who cannot afford childcare, thereby reducing health disparities and inequities. “I’m very grateful to CMS for providing Medicare coverage. Having seen what a powerful difference this program of lifestyle changes can make, I appreciate very much that it is now available to all eligible Medicare beneficiaries with heart disease who can benefit from it,” Dr. Ornish said.

About the Preventive Medicine Research Institute 

The Preventive Medicine Research Institute (PMRI), a 501(c)(3) nonprofit organization, was founded in 1984 by Dean Ornish, M.D., to conduct pioneering research evaluating the power of lifestyle medicine and to make healthy lifestyle changes more widely available to those who can benefit from them. PMRI’s research uses the latest in high-tech medical and scientific technologies to assess the benefits of these low-tech and low-cost lifestyle changes. For more information about PMRI’s four decades of peer-reviewed lifestyle medicine research, please visit https://pmri.org.

The post Lifestyle Changes Significantly Improve Cognition and Function in Early Alzheimer’s Disease for the First Time in a Randomized Controlled Trial appeared first on Medika Life.